<DOC>
	<DOCNO>NCT01916109</DOCNO>
	<brief_summary>The purpose study find use combination standard chemotherapy ( gemcitabine carboplatin ) plus new drug ( panitumumab ) help shrink tumor patient undergoes surgery bladder cancer .</brief_summary>
	<brief_title>Study Gemcitabine , Carboplatin , Panitumumab ( GCaP ) Neoadjuvant Chemotherapy Patients With Muscle-Invasive Bladder Cancer</brief_title>
	<detailed_description />
	<mesh_term>Urinary Bladder Neoplasms</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Histologically confirm muscle invasive transitional cell carcinoma bladder MSKCC ( Note : urothelial carcinoma invade prostatic stroma histologic muscle invasion allow , provide extent disease confirm via image and/or EUA . ) Clinical stage T2T4a N0/X M0 disease . Medically appropriate candidate radical cystectomy per MSKCC attend urologic oncologist Karnofsky Performance Status ≥ 80 % Age ≥ 18 year age Required Initial Laboratory Values : Absolute neutrophil count ≥ 1500 cells/mm3 Platelets ≥ 100,000 cells/mm3 Hemoglobin ≥ 9.0g/dL Bilirubin ≤ 1.5 upper limit normal ( ULN ) institution Aspartate transaminase ( AST ) alanine transaminase ( ALT ) ≤ 2.5 x ULN institution Alkaline phosphatase ≤ 2.5 x ULN institution Serum magnesium &gt; 1.4 mEq/L Serum creatinine ≤ 2.0 mg/dL Cisplatin ineligibility base one follow criterion : Estimated glomerular filtration rate ( eGFR ) 3059 ml/min/1.73m2 use CKDEPI equation : ( http : //nephron.org/MDRD_GFR.cgi ) : eGFR = 141 x min ( Scr/k , 1 ) x max ( Scr/k , 1 ) 1.209 x 0.993Age x 1.018 [ female ] x 1.159 [ black ] Scr serum creatinine , k 0.7 female 0.9 male , 0.329 female 0.411 male , min indicate minimum Scr/k 1 , max indicate maximum Scr/k 1 . Grade 2 sensory neuropathy Grade 2 hearing loss Patients must provide pretreatment saliva sample genomic analysis . Prior systemic chemotherapy ( prior intravesical therapy allow ) Serious intercurrent medical psychiatric illness . Prior radiation therapy bladder . Concomitant use investigational drug Any follow within 6 month prior study drug administration : myocardial infarction , grade 2 great peripheral vascular disease , arterial thrombotic event , visceral arterial ischemia , cerebrovascular ischemia , transient ischemic attack , percutaneous transluminal angioplasty stent , unstable angina . Symptomatic and/or serious uncontrolled arrhythmia Symptomatic congestive heart failure ( NYHA class III IVI ) History interstitial lung disease e.g . pneumonitis pulmonary fibrosis evidence interstitial lung disease baseline chest CT scan . History medical psychiatric condition laboratory abnormality opinion investigator may increase risk associate study participation investigational product ( ) administration may interfere interpretation result . Major surgery require general anesthesia within 21 day minor surgery within 14 day study enrollment . Subjects must recover surgery related toxicity . Pulmonary embolism , deep vein thrombosis , significant venous event ≤ 8 week enrollment Known allergy hypersensitivity component study treatment ( ) Active infection require systemic treatment uncontrolled infection ≤14 day prior enrollment . Known human immunodeficiency virus ( HIV ) acquire immunodeficiency syndrome ( AIDS ) relate illness . Concurrent treatment another clinical trial . Supportive care trial , surgical clinical trial nontreatment trial , e.g . QOL , allow . Ongoing treatment therapeutic dos warfarin ( low dose warfarin 2 mg po daily thromboembolic prophylaxis allow ) . Pregnancy breastfeed . Patients must surgically sterile postmenopausal , must agree use effective contraception period therapy two ( 2 ) month follow last dose panitumumab . The definition effective contraception base judgment principal investigator designate associate . Male patient must surgically sterile agree use effective contraception .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2016</verification_date>
	<keyword>Gemcitabine</keyword>
	<keyword>Carboplatin</keyword>
	<keyword>Panitumumab</keyword>
	<keyword>( GCaP )</keyword>
	<keyword>radical cystectomy</keyword>
	<keyword>10-103</keyword>
</DOC>